Aims Several randomized trials and a previous meta-analysis have shown significant
benefits from Gp IIb-IIIa inhibitors, especially abciximab. Recent randomized trials (BRAVE-3 …

Background Concerns have emerged regarding a higher risk of stent thrombosis after drug-
eluting stent (DES) implantation, especially in the setting of ST-segment elevation …

Background The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the
incidence of major adverse cardiovascular events when administered at hospital admission …

Objective To examine the potential for publication bias, data availability bias, and reviewer
selection bias in recently published meta-analyses that use individual participant data and to …

Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on
Their Use | PLOS Medicine Skip to main content Advertisement PLOS Medicine Browse Current …

Background The most effective magnitude and timing of antiplatelet therapy is important in
patients with acute ST-elevation myocardial infarction (STEMI). We investigated whether the …

Background—The glycoprotein IIb/IIIa receptor inhibitor abciximab has improved the efficacy
of primary percutaneous coronary interventions in patients with acute myocardial infarction …

Objectives To compare a loading dose of 600 mg clopidogrel given in the prehospital phase
versus clopidogrel administered only after the diagnostic angiogram in patients with STEMI …

Introduction Individual participant data (IPD) systematic reviews and meta-analyses are
often considered to be the gold standard for meta-analysis. In the ten years since the first …

Background: Even although time to treatment has been shown to be a determinant of
mortality in primary angioplasty, the potential benefits are still unclear from early …